Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 tofacitinib withdrawal and re-treatment study in moderate to severe chronic plaque psoriasis
2010-020005-32Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib in psoriasis (3 arms), sponsored by Pfizer. Primary endpoints: Maintenance of PASI75 response during withdrawal period, Maintenance of PGA response during withdrawal period and 2 more. Started Oct 2010; status: completed.
02
Drugs
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2010-020005-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020005-32.